Biomarkers of response to PD-1/PD-L1 inhibition

被引：249

作者：

Vareki, Saman Maleki ^{[1
]}

Garrigos, Carmen ^{[2
]}

Duran, Ignacio ^{[2
]}

机构：

[1] Lawson Hlth Res Inst, Canc Res Lab Program, London, ON, Canada

[2] Univ Seville, Inst Biomed Sevilla, CSIC, IBiS,Hosp Univ Virgen Rocio, Seville, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2017年 / 116卷

关键词：

PD-1; PD-L1; Biomarkers; Immunotherapy; Cancer; TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE CHECKPOINT BLOCKADE; PHASE 1B TRIAL; PD-L1; EXPRESSION; MELANOMA PATIENTS; MISMATCH-REPAIR; INDOLEAMINE 2,3-DIOXYGENASE; CLINICAL ACTIVITY; PREDICTIVE BIOMARKER; MUTATIONAL LANDSCAPE;

D O I：

10.1016/j.critrevonc.2017.06.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy is a promising treatment strategy for cancer that has recently shown unprecedented survival benefits in selected patients. A number of immunomodulatory agents that target immune system checkpoints such as the cytotoxic T-Iymphocyte antigen 4 (CTLA-4), the programmed death-1 (PD-1) or its ligand (PD-L1), have received regulatory approval for the treatment of multiple cancers including malignant melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, and recurrent or metastatic head and neck squamous cell carcinoma. Nevertheless, a substantial proportion of patients treated with checkpoint inhibitors have little or no benefit while these treatments are costly and might have associated toxicities. Hence, the establishment of valid predictors of treatment response has become a priority. This review summarizes the current evidence around biomarkers of response to PD-1/PD-L1 inhibition, considering features related to the tumor and to the host immune system. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.

引用

页码：116 / 124

页数：9

共 100 条

[81] Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase VII CheckMate 032 study. [J].

Sharma, Padmanee ;

Bono, Petri ;

Kim, Joseph W. ;

Spiliopoulou, Pavlina ;

Calvo, Emiliano ;

Pillai, Rathi Narayana ;

Ott, Patrick Alexander ;

De Braud, Filippo G. ;

Morse, Michael A. ;

Le, Dung T. ;

Jaeger, Dirk ;

Chan, Emily ;

Harbison, Christopher T. ;

Lin, Chen-Sheng ;

Tschaika, Marina ;

Azrilevich, Alex ;

Rosenberg, Jonathan .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[82] Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma [J].

Simeone, Ester ;

Gentilcore, Giusy ;

Giannarelli, Diana ;

Grimaldi, Antonio M. ;

Caraco, Corrado ;

Curvietto, Marcello ;

Esposito, Assunta ;

Paone, Miriam ;

Palla, Marco ;

Cavalcanti, Ernesta ;

Sandomenico, Fabio ;

Petrillo, Antonella ;

Botti, Gerardo ;

Fulciniti, Franco ;

Palmieri, Giuseppe ;

Queirolo, Paola ;

Marchetti, Paolo ;

Ferraresi, Virginia ;

Rinaldi, Gaetana ;

Pistillo, Maria Pia ;

Ciliberto, Gennaro ;

Mozzillo, Nicola ;

Ascierto, Paolo A. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (07) :675-683

[83] Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy [J].

Sivan, Ayelet ;

Corrales, Leticia ;

Hubert, Nathaniel ;

Williams, Jason B. ;

Aquino-Michaels, Keston ;

Earley, Zachary M. ;

Benyamin, Franco W. ;

Lei, Yuk Man ;

Jabri, Bana ;

Alegre, Maria-Luisa ;

Chang, Eugene B. ;

Gajewski, Thomas F. .

SCIENCE, 2015, 350 (6264) :1084-1089

[84] A Phase I study of indoximod in patients with advanced malignancies [J].

Soliman, Hatem H. ;

Minton, Susan E. ;

Han, Hyo Sook ;

Ismail-Khan, Roohi ;

Neuger, Anthony ;

Khambati, Fatema ;

Noyes, David ;

Lush, Richard ;

Chiappori, Alberto A. ;

Roberts, John D. ;

Link, Charles ;

Vahanian, Nicholas N. ;

Mautino, Mario ;

Streicher, Howard ;

Sullivan, Daniel M. ;

Antonia, Scott J. .

ONCOTARGET, 2016, 7 (16) :22928-22938

[85]

Starr Phoebe, 2015, Am Health Drug Benefits, V8, P16

[86] Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy [J].

Swaika, Abhisek ;

Hammond, William A. ;

Joseph, Richard W. .

MOLECULAR IMMUNOLOGY, 2015, 67 (02) :4-17

[87] Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy [J].

Topalian, Suzanne L. ;

Taube, Janis M. ;

Anders, Robert A. ;

Pardoll, Drew M. .

NATURE REVIEWS CANCER, 2016, 16 (05) :275-287

[88] PD-1 blockade induces responses by inhibiting adaptive immune resistance [J].

Tumeh, Paul C. ;

Harview, Christina L. ;

Yearley, Jennifer H. ;

Shintaku, I. Peter ;

Taylor, Emma J. M. ;

Robert, Lidia ;

Chmielowski, Bartosz ;

Spasic, Marko ;

Henry, Gina ;

Ciobanu, Voicu ;

West, Alisha N. ;

Carmona, Manuel ;

Kivork, Christine ;

Seja, Elizabeth ;

Cherry, Grace ;

Gutierrez, Antonio J. ;

Grogan, Tristan R. ;

Mateus, Christine ;

Tomasic, Gorana ;

Glaspy, John A. ;

Emerson, Ryan O. ;

Robins, Harlan ;

Pierce, Robert H. ;

Elashoff, David A. ;

Robert, Caroline ;

Ribas, Antoni .

NATURE, 2014, 515 (7528) :568-+

[89] Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer [J].

Twyman-Saint Victor, Christina ;

Rech, Andrew J. ;

Maity, Amit ;

Rengan, Ramesh ;

Pauken, Kristen E. ;

Stelekati, Erietta ;

Benci, Joseph L. ;

Xu, Bihui ;

Dada, Hannah ;

Odorizzi, Pamela M. ;

Herati, Ramin S. ;

Mansfield, Kathleen D. ;

Patsch, Dana ;

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

Ishwaran, Hemant ;

Mick, Rosemarie ;

Pryma, Daniel A. ;

Xu, Xiaowei ;

Feldman, Michael D. ;

Gangadhar, Tara C. ;

Hahn, Stephen M. ;

Wherry, E. John ;

Vonderheide, Robert H. ;

Minn, Andy J. .

NATURE, 2015, 520 (7547) :373-+

[90]

University of Chicago Medical Center, 2015, PEMBR SHOWS REAL PRO, P29

← 1 2 3 4 5 6 7 8 9 10 →